Left Ventricular Dysfunction Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Left Ventricular Dysfunction – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Left Ventricular Dysfunction – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 4 and 1 respectively.

Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular)

Companies Mentioned

• Bayer AG
• Innopharmax Inc
• Mesoblast Ltd
• Quantum Genomics SA
• Takeda Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4g1i3c

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900